We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Somatrogon

News List

Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency drugs.com
January 21, 2022
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) issued..
EMA’s CHMP adopts positive opinion for Pfizer’s and OPKO’s somatrogon for GHD treatment Pharmaceutical-Business-Review
December 21, 2021
A once-weekly long-acting recombinant human growth hormone, somatrogon is intended for treating children from three years of age and adolescents experiencing growth disturbance because of inadequate secretion of growth hormone.
EMA validates Pfizer and OPKO’s somatrogon marketing application for review pharmaceutical-business-review
March 04, 2021
The European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for Pfizer and OPKO’s somatrogon, for review.